CHICAGO--(BUSINESS WIRE)--Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy. The regimen containing 150 mg fosaprepitant dimeglumine was not inferior to the regimen with oral aprepitant. Results of the study, known as EASE-017, will be presented on June 8th at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, during a discussion on the poster titled "Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting."
